The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinical benefits of sequential administration of docetaxel and intermittent erlotinib as a second-line therapy for advanced non-small cell lung cancer (NSCLC): A phase II randomized study.
Francisco Aparisi
No relevant relationships to disclose
Alfredo Sanchez-Hernandez
No relevant relationships to disclose
Vicente Giner
No relevant relationships to disclose
José Muñoz-Langa
No relevant relationships to disclose
Gaspar Esquerdo
No relevant relationships to disclose
Antonio López Jiménez
No relevant relationships to disclose
Javier Garde
No relevant relationships to disclose
Jose Garcia Sanchez
No relevant relationships to disclose
Oscar Juan Vidal
No relevant relationships to disclose